• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Diomics, Bonne Santé Group enter strategic alliance

March 29, 2021 By Sean Whooley

Diomics Bonne SanteDiomics and Bonne Santé Group announced today that they entered into a strategic alliance to develop a line of Diocare products.

San Diego-based Diomics and Miami-based Bonne Santé Group, which operated through its Bonne Santé Natural Manufacturing division, entered the agreement in an effor tto develop, launch and distribute the Diocare products formulated to address the COVID-19 pandemic, according to a news release.

Diomics’ product line includes Diocare nasal biome defense spray, Diocare dual IgG/IgA respiratory immunity capsules, Diocare week1 interferon support drink mix, Diocare cough relief and immune health syrup, Diocare cough relief and immune health soft chews and the Diocare anti-fatigue and neuroprotective symptom relief capsules.

“The Diocare product line is our best of nature response to supporting people around the world as they seek protective, symptom support and recovery strategies as we all make our way through this pandemic together,” Diomics CMO Bill Shepard said in the release.

“We are extraordinarily pleased that Diomics chose Bonne Santé to be its partner in the development and rollout of Diocare™,” added Bonne Santé CEO Ryan Zackon. “There could not be a more important and relevant product brought to market given the world we are now living in. Bonne Santé Natural Manufacturing prides itself on the provision of our world-class services ranging from formulation and manufacturing to supply chain as a service as we bring Diocare to market.”

Filed Under: Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: Bonne Sante Group, coronavirus, COVID-19, Diomics

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS